This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Becton Dickinson Crecimiento futuro

Future controles de criterios 1/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Becton Dickinson.

Información clave

15.4%

Tasa de crecimiento de los beneficios

15.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.1%
Tasa de crecimiento de los ingresos	4.8%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	30 May 2023

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

NYSE:BDXB - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2025	21,510	2,973	3,916	5,081	10
9/30/2024	20,344	2,457	3,902	4,666	15
9/30/2023	19,258	2,087	3,872	4,134	15
3/31/2023	18,809	1,556	1,144	2,101	N/A
12/31/2022	18,738	1,486	1,496	2,494	N/A
9/30/2022	18,870	1,545	1,796	2,769	N/A
6/30/2022	18,958	1,413	1,465	2,575	N/A
3/31/2022	18,924	1,430	2,041	3,141	N/A
12/31/2021	18,534	1,079	2,620	3,751	N/A
9/30/2021	19,131	1,514	3,416	4,610	N/A
6/30/2021	19,066	1,486	4,222	5,177	N/A
3/31/2021	18,313	1,379	4,150	5,064	N/A
12/31/2020	18,207	1,507	3,476	4,359	N/A
9/30/2020	16,074	245	2,728	3,497	N/A
6/30/2020	16,917	786	2,474	3,429	N/A
3/31/2020	17,414	923	2,509	3,499	N/A
12/31/2019	17,355	760	2,835	3,798	N/A
9/30/2019	17,290	1,081	2,373	3,330	N/A
6/30/2019	17,108	784	2,359	3,265	N/A
3/31/2019	17,036	926	2,009	2,875	N/A
12/31/2018	17,063	894	1,906	2,790	N/A
9/30/2018	15,983	159	1,970	2,865	N/A
6/30/2018	14,747	621	1,837	2,685	N/A
3/31/2018	13,503	-99	1,681	2,527	N/A
12/31/2017	12,251	294	1,762	2,555	N/A
9/30/2017	12,093	1,030	1,823	2,550	N/A
6/30/2017	12,158	759	1,374	2,129	N/A
3/31/2017	12,321	1,314	1,872	2,579	N/A
12/31/2016	12,419	1,309	N/A	2,411	N/A
9/30/2016	12,483	976	N/A	2,559	N/A
6/30/2016	12,312	1,139	N/A	2,532	N/A
3/31/2016	12,234	810	N/A	2,236	N/A
12/31/2015	11,217	688	N/A	1,907	N/A
9/30/2015	10,282	695	N/A	1,730	N/A
6/30/2015	9,410	815	N/A	1,591	N/A
3/31/2015	8,448	1,079	N/A	1,492	N/A
12/31/2014	8,468	1,150	N/A	1,677	N/A
9/30/2014	8,446	1,185	N/A	1,746	N/A
6/30/2014	8,345	974	N/A	1,876	N/A
3/31/2014	8,239	941	N/A	1,830	N/A
12/31/2013	8,169	930	N/A	1,626	N/A
9/30/2013	8,054	929	N/A	1,505	N/A
6/30/2013	7,920	1,114	N/A	1,405	N/A
3/31/2013	7,848	1,132	N/A	1,595	N/A
12/31/2012	7,776	1,131	N/A	1,679	N/A
9/30/2012	7,708	1,110	N/A	1,760	N/A
6/30/2012	7,729	1,120	N/A	1,733	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: BDXB's forecast earnings growth (15.4% per year) is above the savings rate (2.1%).

Beneficios vs. Mercado: BDXB's earnings (15.4% per year) are forecast to grow slower than the US market (15.7% per year).

Beneficios de alto crecimiento: BDXB's earnings are forecast to grow, but not significantly.

Ingresos vs. Mercado: BDXB's revenue (4.8% per year) is forecast to grow slower than the US market (8% per year).

Ingresos de alto crecimiento: BDXB's revenue (4.8% per year) is forecast to grow slower than 20% per year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Insufficient data to determine if BDXB's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Becton Dickinson Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Becton, Dickinson and Company Provides Earnings Guidance for the Year 2023

Becton, Dickinson and Company Raises Revenue Guidance for the Full-Year 2022

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2022

Becton, Dickinson and Company Revises Revenue Guidance for the Fiscal Year 2022

Recent updates

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Becton, Dickinson and Company Receives FDA 510(k) Clearance for Updated BD Alaris™? Infusion System

Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023

STERIS Corporation agreed to acquire Surgical Instrumentation platform from Becton, Dickinson and Company for $540 million.

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test

Becton, Dickinson and Company Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery

Becton, Dickinson and Company Provides Earnings Guidance for the Year 2023

BD (Becton, Dickinson and Company) Declares Quarterly Dividend, Payable on March 31, 2023

Becton, Dickinson and Company Introduces Fully Automated Robotic Track System for Microbiology Labs

Becton, Dickinson and Company and CerTest Biotec Announce Emergency Use Authorization from U.S. Food and Drug Administration for Molecular Polymerase Chain Reaction Assay for Mpox Virus Detection

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company to Report Q1, 2023 Results on Feb 02, 2023

Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023

Becton, Dickinson and Company Board Increases Quarterly Dividend, Payable on December 30, 2022

Becton, Dickinson and Company to Report Fiscal Year 2022 Results on Nov 10, 2022

Becton, Dickinson and Company Appoints Eric Borin President of Medication Delivery Solutions

BD Launches Cloud Software Solution to Streamline Flow Cytometry Research

BD, Certest Biotec Announce US Commercial Launch of Monkeypox Assay

Becton, Dickinson and Company Launches Next Generation Prefillable Vaccine Syringe Designed for Reliability, Efficiency

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company Raises Revenue Guidance for the Full-Year 2022

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Becton, Dickinson and Company Certest Biotec Announce Commercial Launch of Monkeypox Test

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2022

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Parata Systems, LLC from Frazier Healthcare Partners.

Becton, Dickinson and Company to Report Q3, 2022 Results on Aug 04, 2022

Becton, Dickinson and Company Announces Management Changes

Becton, Dickinson and Company Launches Combination Test for COVID-19, Influenza A/B and Respiratory Syncytial Virus

BD Announces Voluntary Recall on Intraosseous Products

Becton, Dickinson and Company Appoints Simon Campion as Executive Vice President and President of the Medical Segment, Effective July 1, 2022

Becton, Dickinson and Company (NYSE:BDX) (BD) entered into a definitive agreement to acquire Parata Systems, LLC from Frazier Healthcare Partners for $1.5 billion.

Becton, Dickinson and Company Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Platform in the U.S

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2022

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 30, 2022

New Becton, Dickinson and Company Reagents Enable Researchers to Break Through Resolution Boundaries in Flow Cytometry

Becton, Dickinson and Company to Report Q2, 2022 Results on May 05, 2022

Becton, Dickinson and Company Announces Management Changes

Becton, Dickinson and Company Announces Retirement of Alberto Mas as Executive Vice President and President of the Medical Segment, Effective September 30, 2022

Becton, Dickinson and Company Appoints William Bill Brown to Board of Directors

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company Revises Revenue Guidance for the Fiscal Year 2022

Becton, Dickinson and Company (NYSE:BDX) acquired Cytognos, SL from Vitro S.A.

Becton, Dickinson and Company Receives 510(K) Clearance from the U.S. Food and Drug Administration for the BD Kiestra™ Identifa System

BD Announces New Distribution and Retail Partners for Bd Veritor At-Home Covid-19 Test

Becton, Dickinson and Company (NYSE:BDX) acquired Scanwell Health, Inc.

BD Expands Fully Automated High-Throughput Molecular Diagnostic Platform for Core Labs

Becton, Dickinson and Company (NYSE:BDX) acquired Tissuemed Ltd.

Becton, Dickinson and Company (NYSE:BDX) acquired Venclose, Inc.

Becton, Dickinson and Company Receives Emergency Use Authorization for First At-Home COVID-19 Test to Use Smartphone to Interpret, Deliver Results

BD (Becton, Dickinson and Company) Announces the Launch of A New Benchtop Cell Analyzer

Becton, Dickinson and Company (NYSE:BDX) acquired ZebraSci Inc.

BD Announces Expanded 510(k) Clearance for At-Home System for Ascites

Becton, Dickinson and Company Launches Urine Culture Application

Becton, Dickinson and Company (NYSE:BDX) acquired BD Surgiphor Sterile Wound Irrigation System from Orthophor, LLC.

Becton, Dickinson and Company Announces Industry-First CE Marked Assay for HPV Screening from At-Home Self-Collected Vaginal Samples

BD Announces Intent to Spin Off Diabetes Care Business to Enhance Focus on Innovation and Priority Growth Markets

BD Announces Enrollment in Post-Market Studies of the WavelinQ™ Arteriovenous Endovascular Fistula

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 30, 2021

BD Announces FDA 510(k) Submission for BD Alaris™ System

BD Announces Collaboration with ImageMover for Rapid Antigen Test Reporting

Becton, Dickinson and Company (NYSE:BDX) acquired GSL Solutions, Inc.

BD and Scanwell Health Announces Collaboration for At-Home Rapid Test for COVID-19

BD Announces Emergency Use Authorization, CE Mark for Combination Molecular Diagnostic to Detect SARS-CoV-2, Influenza A+B in Single Test

Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2021

Becton, Dickinson and Company Announces New Clinical Data Found Robust Evidence Using A Vascular Care Solution

Becton, Dickinson and Company Announces Board Changes